- Home
- NCL vs RLMD Comparison
NCL vs RLMD Comparison
Compare NCL & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCL
- RLMD
- Stock Information
- Founded
- NCL 2013
- RLMD 2004
- Country
- NCL United States
- RLMD United States
- Employees
- NCL N/A
- RLMD N/A
- Industry
- NCL
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- NCL
- RLMD Health Care
- Exchange
- NCL Nasdaq
- RLMD Nasdaq
- Market Cap
- NCL 21.7M
- RLMD 22.0M
- IPO Year
- NCL 2023
- RLMD N/A
- Fundamental
- Price
- NCL $0.18
- RLMD $0.68
- Analyst Decision
- NCL
- RLMD Buy
- Analyst Count
- NCL 0
- RLMD 3
- Target Price
- NCL N/A
- RLMD $5.00
- AVG Volume (30 Days)
- NCL 16.6M
- RLMD 521.4K
- Earning Date
- NCL 08-13-2025
- RLMD 08-06-2025
- Dividend Yield
- NCL N/A
- RLMD N/A
- EPS Growth
- NCL N/A
- RLMD N/A
- EPS
- NCL N/A
- RLMD N/A
- Revenue
- NCL $15,576,857.00
- RLMD N/A
- Revenue This Year
- NCL N/A
- RLMD N/A
- Revenue Next Year
- NCL N/A
- RLMD N/A
- P/E Ratio
- NCL N/A
- RLMD N/A
- Revenue Growth
- NCL 47.13
- RLMD N/A
- 52 Week Low
- NCL $0.15
- RLMD $0.24
- 52 Week High
- NCL $1.52
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- NCL 36.05
- RLMD 52.86
- Support Level
- NCL $0.19
- RLMD $0.67
- Resistance Level
- NCL $0.32
- RLMD $0.76
- Average True Range (ATR)
- NCL 0.18
- RLMD 0.08
- MACD
- NCL -0.07
- RLMD -0.02
- Stochastic Oscillator
- NCL 0.80
- RLMD 11.40
About NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.